CORT Quote, Financials, Valuation and Earnings

Amicus Therapeutics, Inc. has a net margin of 9.32% compared to Corcept Therapeutics, Inc.'s net margin of 10.24%. Corcept Therapeutics, Inc.'s return on equity of 16% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

Corcept Therapeutics, Inc. has a consensus price target of $91.00, signalling upside risk potential of 150.62%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.83 which suggests that it could grow by 3.37%. Given that Corcept Therapeutics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Amicus Therapeutics, Inc..

Corcept Therapeutics, Inc. has a beta of 0.232, which suggesting that the stock is 76.804% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.

Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Corcept Therapeutics, Inc. quarterly revenues are $207.6M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Corcept Therapeutics, Inc.'s net income of $19.4M is higher than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 41.49x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 5.86x versus 7.34x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 9.32% compared to Corcept Therapeutics, Inc.'s net margin of 20.83%. Corcept Therapeutics, Inc.'s return on equity of 16% beat Johnson & Johnson's return on equity of 33.27%.

Corcept Therapeutics, Inc. has a consensus price target of $91.00, signalling upside risk potential of 150.62%. On the other hand Johnson & Johnson has an analysts' consensus of $212.00 which suggests that it could fall by -2.76%. Given that Corcept Therapeutics, Inc. has higher upside potential than Johnson & Johnson, analysts believe Corcept Therapeutics, Inc. is more attractive than Johnson & Johnson.

Corcept Therapeutics, Inc. has a beta of 0.232, which suggesting that the stock is 76.804% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.341, suggesting its less volatile than the S&P 500 by 65.861%.

Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.36% to investors and pays a quarterly dividend of $1.30 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Corcept Therapeutics, Inc. quarterly revenues are $207.6M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Corcept Therapeutics, Inc.'s net income of $19.4M is lower than Johnson & Johnson's net income of $5.1B. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 41.49x while Johnson & Johnson's PE ratio is 19.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 5.86x versus 5.62x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Ultragenyx Pharmaceutical, Inc. has a net margin of 9.32% compared to Corcept Therapeutics, Inc.'s net margin of -112.81%. Corcept Therapeutics, Inc.'s return on equity of 16% beat Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83%.

Corcept Therapeutics, Inc. has a consensus price target of $91.00, signalling upside risk potential of 150.62%. On the other hand Ultragenyx Pharmaceutical, Inc. has an analysts' consensus of $63.90 which suggests that it could grow by 180.88%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Corcept Therapeutics, Inc., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Corcept Therapeutics, Inc..

Corcept Therapeutics, Inc. has a beta of 0.232, which suggesting that the stock is 76.804% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical, Inc. has a beta of 0.155, suggesting its less volatile than the S&P 500 by 84.518%.

Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical, Inc. pays out -- of its earnings as a dividend.

Corcept Therapeutics, Inc. quarterly revenues are $207.6M, which are larger than Ultragenyx Pharmaceutical, Inc. quarterly revenues of $159.9M. Corcept Therapeutics, Inc.'s net income of $19.4M is higher than Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 41.49x while Ultragenyx Pharmaceutical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 5.86x versus 3.52x for Ultragenyx Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics Corp. has a net margin of 9.32% compared to Corcept Therapeutics, Inc.'s net margin of 42.36%. Corcept Therapeutics, Inc.'s return on equity of 16% beat United Therapeutics Corp.'s return on equity of 19.2%.

Corcept Therapeutics, Inc. has a consensus price target of $91.00, signalling upside risk potential of 150.62%. On the other hand United Therapeutics Corp. has an analysts' consensus of $530.84 which suggests that it could grow by 13%. Given that Corcept Therapeutics, Inc. has higher upside potential than United Therapeutics Corp., analysts believe Corcept Therapeutics, Inc. is more attractive than United Therapeutics Corp..

Corcept Therapeutics, Inc. has a beta of 0.232, which suggesting that the stock is 76.804% less volatile than S&P 500. In comparison United Therapeutics Corp. has a beta of 0.840, suggesting its less volatile than the S&P 500 by 15.965%.

Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. United Therapeutics Corp. pays out -- of its earnings as a dividend.

Corcept Therapeutics, Inc. quarterly revenues are $207.6M, which are smaller than United Therapeutics Corp. quarterly revenues of $799.5M. Corcept Therapeutics, Inc.'s net income of $19.4M is lower than United Therapeutics Corp.'s net income of $338.7M. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 41.49x while United Therapeutics Corp.'s PE ratio is 17.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 5.86x versus 7.24x for United Therapeutics Corp.. Usually stocks with elevated PS ratios are considered overvalued.